• About Us
        • Leadership Team
        • Board of Directors
        • Careers
        • Contact Us
      • Areas of Focus
        • Paroxysmal supraventricular tachycardia (PSVT)
        • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
      • Research & Development
        • Etripamil
        • Publications
        • Clinical Trials
        • Patient Access
      • Investors & Media
        • News & Events
        • Stock Information
        • Financial Information
        • Corporate Governance
        • Investor Resources
    Milestone Pharma
    Close

    Search

    Recent Posts

    • Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial – The Lancet
    • Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia
    • Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
    • Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
    • Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings

    Recent Comments

      Archives

      • June 2023
      • May 2023
      • February 2023
      • November 2022
      • October 2022
      • September 2022
      • May 2022
      • November 2021
      • July 2021
      • May 2021
      • March 2021
      • May 2020
      • January 2020
      • December 2019
      • May 2019

      Categories

      • Publication

      Meta

      • Log in
      • Entries feed
      • Comments feed
      • WordPress.org
      Careers | Contact Us | Privacy Policy | Consumer Health Data Privacy Policy | Terms of Use
      © Milestone Pharmaceuticals USA, Inc. All Rights Reserved.
      • English: United States
        • English: Canada
        • Français (French): Canada

      Our website content is tailored by geographical region to comply with local regulatory requirements. Please select which country’s site you’d like to visit.

      • English: United States
      • English: Canada
      • Français (French): Canada